跳至主要内容
临床试验/NCT04115657
NCT04115657已完成不适用

The Effect of Different Starches of Boba Pearls and Sugar Substitutes Used in Milk Tea on Glycaemia, Insulinaemia and Appetite Control (Pearl Study)

Clinical Nutrition Research Centre, Singapore1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2019年5月2日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12
试验地点
1
主要终点
Postprandial insulin

研究概览

简要总结

The first objective is to investigate the effect of boba pearls made from different starches on glycaemia, insulinaemia and appetite control. The second objective is to investigate the effects of various sugar blends of sucrose with sugar substitutes in milk tea on glycaemia, insulinaemia and appetite control.

详细描述

Design: There are two parts to this study. Participants will voluntarily choose to participate in either one or both parts of the study during the first screening session. Part A: Testing the effects of boba pearls using different starches. Part B: Testing the effects of milk-based tea with different sugar blends of sucrose with sugar substitutes with a standard type of boba pearl

Both parts of the study will have a randomized, nonblinded, crossover design. Screening will occur before the study commences. Participants will be asked to return on four non-consecutive days (Part A) and two-three non-consecutive days (Part B) with a wash out period of at least 2 days to avoid crossover effects. In both parts of the study, the test foods will be consumed with a carbohydrate-based food (for example: bread, biscuit etc.)

Study protocol Screening session: All potential participants will be asked to attend one screening session to ensure they are eligible to be enrolled into the study. After which, they will attend either four test sessions (Part A) and/or two-three test sessions (Part B). If the participant participates in Part A of the study, they will only be required to attend two test sessions in Part B as they would have completed the control session in Part A. If participants decide to participate only in Part B of the study, they will have to complete three test sessions. During the first screening session, participants will receive an informed consent form and be given ample time to go through it and rectify any queries they have. If they decide to take part in the study, they will be asked to sign the informed consent form. They will then be asked to complete a screening questionnaire, baseline measurements including anthropometric measurements, blood pressure, and fasting blood glucose will be collected from each participant in order to determine their eligibility. During the test sessions, participants' glycaemic, insulinaemic and appetite responses to the test meals will be measured. The test duration for each session will be 4 hours. Participants will be instructed to avoid strenuous physical activity for at least 3 days and avoid caffeine and alcohol consumption for at least 1 day prior to visiting the CNRC for their study trials. Participants will be provided with a standardised dinner meal (consisting of rice/noodles, vegetables, meat, drink/pudding) and asked to refrain from alcohol and exercise the day before their testing sessions. Screening questionnaire: The screening questionnaire will include contact information, demographic and general health details. This information will be used to determine whether the participant is eligible for the study, as well as to check for any possible confounders that may influence the study outcomes.

Anthropometric measurements: Body weight and body composition will be measured using bioelectrical impedance analysis. Height will be measured using a stadiometer in order to calculate participants' BMI. Blood pressure will also be measured. All measurements will be taken in duplicate during the screening session. Waist circumference will be measured at the minimum circumference between the iliac crest and the rib cage. Hip circumference will be measured at the maximum protuberance of the buttocks. Biceps and triceps skinfold measurements will also be taken. Blood pressure will be measured using an Omron blood pressure monitor (Model HEM-907) at baseline. Participants will be seated for five minutes before blood pressure is measured. Measurements will be taken in duplicate and the averaged results will be recorded.

Blood collection: Participants will be asked to attend the testing sessions after an overnight fast of ten hours. After a 15-minute rest period, they will have a cannula inserted in their arm to obtain blood samples at regular intervals. One fasting blood sample will be collected by venous cannulation. 3 millilitres (ml) of venous blood will be collected into Vacutainers® (Belton Dickinson Diagnostics) containing disodium EDTA for the analyses of plasma glucose, insulin concentrations. Participants will then consume treatment meal within15 minutes. Blood samples will be taken at 15, 30, 45, 60, 90, 120, 150 and 180 minutes. The amount of blood that will be collected at every time point will be about 0.6 teaspoon of blood (approximately 3 ml). The accumulative amount per test session will not be more than 5.4 teaspoons of blood (approximately 27 ml), and the accumulative amount for the entire study duration will be approximately 108ml of blood for Part A and for Part B, 81ml of blood (3 test sessions) or 54ml of blood (2 test sessions). The blood samples collected at each time point will be measured for glucose and insulin. Glycaemic and insulinaemic responses will be determined using the method described by Wolever and Jenkins. The area under the curve will be determined as the area of those increments above baseline only. Metabolic satiety: At the same time intervals, the participants will be instructed to fill in visual analogue scale (VAS) on feelings of fullness, hunger, desire to eat and prospective food consumption. VAS are 100 mm continuous lines anchored with opposing answers to a specific question asked either on a computer or on a hard copy. The specific questions asked will be, 'How hungry do you feel?', 'How full do you feel?', 'How strong is your desire to eat?', 'How much more food do you think you can eat?'. The participants will be instructed to make a mark on the line which corresponds with their subjective feeling. Only for Part A of the study, upon completion of the blood collection and before lunch, participants will be asked to drink a mouthful of the bubble tea with pearls (standardised serving size) and to masticate the boba pearls as they would naturally do. They will be asked to raise their hands once they swallow the pearls. The researcher would have counted the number of chews (x chews) to reach the swallow point (when participants raise their hands). Participants will be asked to rinse their mouth, have the second mouthful and chew x times before expectorating the bolus for particle size analysis. Three replicates will be collected. Boluses will be placed in a petri dish and suspended in distilled water to separate the particles before an image is captured for image analysis. Samples will be discarded upon completion of image analysis.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
None

入排标准

年龄范围
21 Years 至 40 Years(Adult)
性别
Male
接受健康志愿者
是

入选标准

  • •Healthy Asian Chinese
  • •Aged between 21 - 40 years
  • •≥45kg body weight
  • •Body mass index between 18.5 to 25.0 kg/m2
  • •Normal blood pressure ≤140/90 mmHg
  • •Fasting blood glucose <5.6 mmol/L

排除标准

  • •Allergic/intolerant to any of the test foods to be administered, or any of the following common food and ingredients: eggs, fish, milk, peanuts, tree nuts, shellfish, soya, wheat, gluten, cereal, fruits, dairy products, meat, vegetable, sugar and sweetener, natural food colourings or flavourings, sulphites etc.
  • •Anyone with intentional food restrictions
  • •People with known glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency)
  • •Having metabolic or cardiovascular diseases (such as diabetes, hypertension, heart condition, etc.)
  • •Having medical conditions and/or taking medications known to affect glycaemia (glucocorticoids, thyroid hormones, thiazide diuretics)
  • •Taking any prescribed medication or dietary supplements which may interfere with the study measurements
  • •Individuals who have any major organ dysfunction (eg. cardiovascular, respiratory, hepatic, renal, gastrointestinal) that may influence taste, olfaction, appetite, digestion, metabolism, absorption or elimination of test foods, nutraceutical or drug
  • •Excessive alcohol consumption: consuming ≥ 6 alcoholic drinks per week
  • •Have known Chronic infection or known to suffer from or have previously suffered from or is a carrier of Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Human Immunodeficiency Virus (HIV)
  • •Have active Tuberculosis (TB) or currently receiving treatment for TB
  • •Individuals who partake in sports at the competitive and/or endurance levels
  • •A team member of the study or is an immediate family member (Immediate family defined as a spouse, parent, child, or sibling, whether biological or legally adopted)

研究组 & 干预措施

Starch 1

Experimental

Tapioca starch

干预措施: Starch 1 (Other)

Starch 2

Experimental

High amylose

干预措施: Starch 2 (Other)

Starch 3

Experimental

Kithul flour

干预措施: Starch 3 (Other)

Starch 4

Experimental

Sago flour

干预措施: Starch 4 (Other)

Sugar 1

Experimental

Pure palatinose

干预措施: Sugar 1 (Other)

Sugar 2

Experimental

Blend of sucrose and palatinose

干预措施: Sugar 2 (Other)

结局指标

主要结局

Postprandial insulin

时间窗: From 0 to 180 minutes

Venous blood plasma measured using the COBAS

Postprandial glucose

时间窗: From 0 to 180 minutes

Venous blood plasma measured using the COBAS

次要结局

  • Appetite control(From 0 to 180 minutes)

研究者

发起方
Clinical Nutrition Research Centre, Singapore
申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验